Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is an effective treatment for anemia both in nondialysis patients with chronic kidney disease (CKD) and in long-term dialysis patients, according to a pair of industry-sponsored trials recently published in the New England Journal of Medicine (NEJM).
Chen N, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med 2019; doi: 10.1056/NEJMoa1813599;
Chen N, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 2019; doi: 10.1056/NEJMoa1901713.